Google DeepMind Uses AI to Target Resistant Infections
The platform labels uncharacterized proteins to accelerate the discovery of new antimicrobials for drug-resistant bacteria.
Updated on Oct. 31, 2026 in Life Sciences
Live Poll
Do you trust that artificial intelligence will successfully solve global health threats like antibiotic resistance?
Google DeepMind is employing its Antigravity agentic development platform to accelerate the discovery of novel antimicrobials. The researchers are utilizing the ProtNLM deep learning model to label and analyze previously uncharacterized protein sequences in the UniProt database.
Why it matters
Antimicrobial resistance (AMR) is a rising global health threat, leaving millions of patients without effective treatment options for infections. Identifying new targets for drugs is essential to address the mortality and economic burden associated with resistant bacteria.
The Google Antigravity platform is used alongside the ProtNLM model to parse the UniProt protein sequence repository. This research-stage methodology aims to identify new drug targets, building on models previously explored by researchers at MIT to treat MRSA.
The players
Google DeepMind
An AI research subsidiary of Alphabet focusing on machine learning and algorithmic problem-solving for scientific discovery.
MIT
A research university exploring the use of generative AI to identify treatments for drug-resistant gonorrhea and MRSA.
The details
ProtNLM is a deep learning model capable of understanding and predicting amino acid sequences. Researchers use this system to label uncharacterized proteins stored in the UniProt database, allowing for a structured evaluation of protein architecture. The Google Antigravity platform then processes these findings to identify viable drug targets for synthetic antimicrobial development.
Timeline
2019: AMR accounted for nearly 5 million global deaths.
2050: AMR is projected to cause 10 million annual deaths.
The Tech Race
This development follows the baseline established by the 2019 AMR global death toll of 5 million. It directly competes with other AI-driven drug discovery programs, such as those at MIT, aimed at addressing the projected 10 million deaths annually by 2050.
This research remains at the laboratory stage and is not currently available for clinical use. It represents a long-term effort to mitigate the 66 trillion pounds of global economic loss projected due to untreatable resistant infections.
The takeaway
The race to combat AMR requires both new predictive models and successful translation from protein labeling to bench testing. Researchers are now working against the projected 2050 milestone of 10 million deaths, making the validation of these machine-learned targets the next critical bottleneck.
Further reading
For broader developments in the field, see our latest coverage in Life Sciences.
Source note: This article includes information reported by Forbes.
Live Poll
Do you trust that artificial intelligence will successfully solve global health threats like antibiotic resistance?
